Children who have previously received chemotherapy, radiation therapy or any anti-leukemic therapy are not eligible for this protocol, with the exception of cytarabine for the treatment of TMD
Metastases located within 3 cm of previously irradiated (< 3Gy per fraction) structures if not a candidate for surgery for these lesions and if:\r\n* Spinal cord previously irradiated to > 40 Gy\r\n* Brachial plexus previously irradiated to > 50 Gy\r\n* Small intestine, large intestine, or stomach previously irradiated to > 45 Gy\r\n* Brainstem previously irradiated to > 50 Gy\r\n* Lung previously irradiated with prior V20 Gy > 35%
Metastases located within 3 cm of the previously irradiated structures:\r\n* Spinal cord previously irradiated to > 40 Gy (delivered in =< 3 Gy/fraction)\r\n* Brachial plexus previously irradiated to > 50 Gy (delivered in =< 3 Gy/fraction)\r\n* Small intestine, large intestine, or stomach previously irradiated to > 45 Gy (delivered in =< 3 Gy/fraction)\r\n* Brainstem previously irradiated to > 50 Gy (delivered in =< 3 Gy/fraction)\r\n* Whole lung previously irradiated with prior V20Gy > 30% (delivered in =< 3 Gy/fraction)\r\n* Primary tumor irradiated with SBRT\r\n* Metastasis irradiated with SBRT
Must have previously received first line treatment regimen
Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study
Received systemic investigational drug within 6 weeks prior to AVB-620 administration or has received AVB-620 previously.
At least 4 months since completion of curative therapy, if given previously
Have previously been enrolled in this study or any other study investigating SM-88 or who have previously received any component of SM-88 in a clinical trial.
All NF-1 patients with a LGG are eligible for Stratum 2, with or without histologic confirmation, provided they have never previously received adjuvant therapy with the exception of surgery
Patients with HGG: Have previously received radiotherapy and temozolomide with a maximum of 2 prior relapses on treatment
Have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor.
The patient has previously received treatment with SL-801 or another investigational agent that inhibits the XPO1/CRM1 pathway.
PHASE IB: Patients in the expansion cohort must have a measurable site of disease according to RECIST (v 1.1) that has not been previously irradiated, or evidence of at least 20% progression in a previously irradiated lesion, and assessed by imaging within 28 days prior to registration for protocol therapy
Patients who have previously received PGG-Betafectin (Betafectin) or Imprime PGG
INCLUSION - PROCUREMENT: Either previously infected with varicella zoster virus (VZV; chicken pox) or previously vaccinated with VZV vaccine
Patients with previously documented macular degeneration or diabetic retinopathy are excluded from the trial
Patients who have previously received recombinant (r)IL-12
Patients who have previously received radiation therapy
Patient has previously taken ruxolitinib or is allergic to components of the study drug
Patients who have previously received either AG120 or venetoclax.
The patient has previously been enrolled in the study or received ESK981
Target tumor in region not in previously irradiated field
STRATUM C: Participants previously treated with a smoothened inhibitor must have received their last dose > 6 months prior to study enrollment
Currently or previously being on hydroxyurea
Previously untreated patients who decline standard therapy for their cancer are allowed to enroll
Subjects may have previously progressed on treatment with one of the 3 agents being used in this trial or treatment with other checkpoint inhibitors, as long as they have recovered from previous toxicity; subjects that previously progressed on treatment with a combination of any 2 of the 3 agents being used in this trial are eligible for the triplet cohort only
The participant has received prior treatment with gemcitabine or docetaxel. Note: Participants previously enrolled in the I5B-MC-JGDJ (NCT02451943) or any other blinded study with olaratumab are not eligible to participate in this trial.
Patients with previously documented macular degeneration or diabetic retinopathy are excluded
Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.
Patient has been previously permanently discontinued from study treatment in the parent protocol.
Subjects who previously received IACS-010759 or oxidative phosphorylation (OXPHOS) inhibitors.
Previously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;
Have previously completed or withdrawn from any study investigating olaratumab.
Patients who previously participated in CH-ACM-01 or OOC-ACM-302
Subject previously dosed with isavuconazonium sulfate.
Participants who have previously received TAS-102
Patients who have previously received systemic topotecan for their tumor
Has previously received a btk inhibitor and had progressive disease during therapy; patients who have previously discontinued btk inhibitor therapy because of intolerance may be considered for eligibility per the assessment of the PI and treating physician if there is reason that the patient may better tolerate btk inhibitor therapy at enrollment versus previously
Subjects who received GCB systemically previously are eligible for participation
Clinical target volume (CTV) size must be < 250 cc, no more than 74 Gy of prior radiation in 2 Gy fractions previously administered
Patients with previously documented macular degeneration or untreated diabetic retinopathy (stable retinopathy is allowed)
Patients must not have previously undergone an intracranial LITT procedure.
Have previously completed, discontinued, or have been withdrawn from this study.
Have previously received maribavir.
Scenario 1: No prior cdk 4/6 inhibitor; if patient has not previously received letrozole, letrozole will be supplied by Novartis; if previously progressed on letrozole, another aromatase inhibitor that the patient has not previously received is allowed, per standard of care (anastrazole or exemestane, not supplied by study); ribociclib will be supplied by Novartis; if patient has previously received letrozole, anastrazole, and exemestane, (s)he is not eligible; for scenario 1, patients are allowed to have started the aromatase inhibitor within 4 consecutive weeks prior to protocol registration; for instance, it is acceptable for patient who will be treated with letrozole in scenario #1, to have started letrozole within 4 consecutive weeks prior to protocol registration; no prior fulvestrant allowed
Since selumetinib is not expected to cause substantial myelosuppression, there will be no limit to number of prior myelosuppressive regimens previously received for NF1 related; or other tumor manifestations
Patients must have previously received at least one standard therapy for their cancer (if available) and have been either non-responders (progressive disease) or have recurred
Patients with HM, as previously defined, without confirmed response to standard, first-line antineoplastic therapy, and/or who do not fulfill all Inclusion Criteria as stated, will be ineligible to participate in this study.
Patients who have previously received alemtuzumab are ineligible
The subject has previously participated in this study.
Patients who have previously received therapeutic radiation therapy to the chest
Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
Patient has previously participated in the Toca 5 trial (Tg 511-15-01).
Patients may not have previously received alisertib
Newly diagnosed Philadelphia chromosome-positive (Ph+) ALL, previously untreated, except for the below allowances:\r\n* Previously received hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (HyperCVAD) cycle 1A +/- cycle 1B\r\n* Previously received induction phase I +/- induction phase II of Berlin-Frankfurt-Munster (BFM)-modeled (pediatric or pediatric-inspired) ALL regimen\r\n* Previously received other representative (modified from HyperCVAD, BFM, or AML-like) ALL induction course, including ABL tyrosine-kinase inhibitor (TKI) plus corticosteroid\r\n* If the patient has received any of the above prior therapy, they may be enrolled, regardless of remission status
Subject previously has entered this study
Patients with previously documented macular degeneration or untreated diabetic retinopathy (stable retinopathy is allowed)
Patients previously exposed to bosutinib are eligible unless they carry T315I
The patient has previously received definitive surgical, radiation, or chemoradiation treatment for HNSCC
Patients with previously documented macular degeneration or diabetic retinopathy are excluded
Previously untreated patients with locoregional-only disease are not eligible
Subjects with metastatic disease exclusively present within a previously irradiated field\r\n* Subjects with metastasis within and outside of previously irradiated field that is eligible for SABR are eligible
Patients may not have previously failed treatment with salvage temozolomide
Patients who have previously received therapeutic radiation therapy to the chest
Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study
Subjects who have been previously randomized into the present study;
Patients may have previously failed non-platinum containing therapy or may never have previously progressed on treatment
Previously diagnosis of alpha- or beta-thalassemia since these patients may have significantly higher PK levels than patients without these disorders
Active intracranial metastases; patients with previously resected intracranial disease and/or previously irradiated intracranial metastases that have been clinically stable for four weeks are eligible
Subjects who had previously received an experimental agent for MDS may not be randomized until a washout period has elapsed since the last dose of that agent.
Participants who have ever previously received any anti-neoplastic agent, including methotrexate, 6-mercaptopurine, 6-thioguanine, vincristine cyclophosphamide, cytarabine (except for IT cytarabine), or any anthracycline, for any reason (e.g., rheumatologic or autoimmune condition) are not eligible
Have previously received maribavir.
Participants may not have been vaccinated previously with any of the synthetic peptides included in this protocol
Subjects who have previously received anetumab ravtansine
Have previously completed or withdrawn from this study or any other study investigating dasatinib; prior treatment with other tyrosine kinases, including afatinib, is acceptable
Symptomatic, previously untreated (with exception of corticosteroids) secretory myeloma
All laboratory and imaging studies must be completed and satisfactory within 30 days of signing the consent document, with the exceptions of: negative serum pregnancy test for women of child-bearing potential which must be negative within 7 days of screening, human leukocyte antigen (HLA)-typing which will not be repeated if performed previously, and pulmonary function tests (PFTs)/cardiac stress tests whose results are valid for 6 months if performed previously
All laboratory and imaging studies must be completed and satisfactory within 30 days of signing the consent document, with the exceptions of: negative serum pregnancy test for women of child-bearing potential must be negative within 7 days of starting vemurafenib, human leukocyte antigen (HLA)-typing which will not be repeated if performed previously, and pulmonary function test (PFTs)/cardiac stress tests whose results are valid for 6 months if performed previously
previously received:
The patient has previously received treatment with SL-401.
Subjects who have previously undergone intraperitoneal chemotherapy
Previously received X4P-001
Have previously completed or withdrawn from this study or any other study investigating LY3039478 or other Notch inhibitors.
Has previously received TAS-102.
If enrolled in Part 2SA, new, growing, or previously untreated lesions since the start of anti-PD-1 therapy.
Received glembatumumab vedotin (CR011-vcMMAE; CDX-011) or other MMAE-containing agents previously.
Subjects must have previously completed standard radiation therapy and been exposed to temozolomide. Patients must be in first or second relapse.
Patients with previously documented macular degeneration or diabetic retinopathy
Patients who have previously received systemic, radiation or other treatment for uterine cancer
Patients must not have previously received a histone deacetylase (HDAC) inhibitor in a clinical trial setting (entinostat, romidepsin, belinostat, panobinostat, vorinostat)
For participants enrolled in the expansion phase: lymphoma classified as either previously untreated Grade 1, 2, or 3a FL that requires treatment or previously untreated advanced DLBCL
Metastases located within 3 cm of the previously irradiated structures:\r\n* Spinal cord previously irradiated to > 40 Gy (delivered in =< 3 Gy/fraction)\r\n* Brachial plexus previously irradiated to > 50 Gy (delivered in =< 3 Gy/fraction)\r\n* Small intestine, large intestine, or stomach previously irradiated to > 45 Gy (delivered in =< 3 Gy/fraction)\r\n* Brain stem previously irradiated to > 50 Gy (delivered in =< 3 Gy/fraction)\r\n* Whole lung previously irradiated with prior volume 20 Gy (V20Gy) > 30% (delivered in =< 3 Gy/fraction)\r\n* Primary tumor irradiated with SBRT\r\n* Metastasis irradiated with SBRT
Patients who received PDGFR inhibitors (imatinib, sunitinib, nilotinib, etc.) previously are excluded (patients who received PDGFR antibody based treatment however are allowed)
Patients who have previously received radiation therapy
Patients may not have received eribulin or lenvatinib previously
Patients who have previously received mithramycin, strontium-89, samarium-153 or rhenium
Patients who have received trabectedin (Yondelis, ET-743) or participated in the phase III clinical study of trabectedin NCT01343277 previously will not be eligible
Patient was previously exposed to PBI 05204.
Not recovered from AEs due to a previously administered therapy
Subjects who have received radiation to the orbit at any time previously
Previously untreated participants are eligible if their tumor(s) are measurable
COHORT II: Patients must not have previously received treatment with chemotherapy for MM
In the Phase 2 portion of the trial only, subjects who have previously received treatment with an inhibitor of IDH.
Patients with previously documented macular degeneration or diabetic retinopathy are ineligible
Previously received eribulin.
Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
Use previously of intra-articular treatment within 4 weeks prior dosing.
Previously untreated patients with lymphoplasmacytic lymphoma (of any subtype: IgG, IgA, IgM) in the asymptomatic phase
Retreatment of previously irradiated tumor will be excluded; this will in general be described as an anticipated overlap of a region that has previously received >= 50 Gy and would now be included within the D90 region of the SBRT plan; there is no restriction on prior stage as long as dosimetry guidelines can be met
Has previously undergone a left sided colon resection.
Subject has received ASP2215 previously.
Must have previously received at least one prior chemotherapeutic regimen for RT.
Previously untreated RT patients deemed ineligible for, or that refuse, intensive chemotherapy are eligible.
COHORT 2 ONLY: A Smoothened inhibitor must have been previously administered as monotherapy
Previously received photodynamic therapy for cholangiocarcinoma
Previously undergone metal stent insertion
No documentation of prior cytotoxic or other therapy for malignancy if such therapy was previously received; Note: This does not apply to patients with synchronous metastases at initial diagnosis
Has previously received X4P-001.
Subjects who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown
Patients who have previously received CDX-011 (CR011-vc monomethyl auristatin E [MMAE]; CDX-011) or other MMAE-containing agents
Patients who have previously received CDX-011 (glembatumumab vedotin) or other monomethyl auristatin E (MMAE)-containing agents
Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN003694-002)
Patients who have previously received eribulin, halichondrin B, or analogues of halichondrin B
Patients who have previously received romidepsin or Abraxane
Patients previously randomized in any other Onyx-sponsored phase 3 trial
Have previously been exposed to MGAH22 in this or any other trial
Patients who are receiving or have received any other investigational agents within 30 days of study day 1, or who have previously received MK-2206 at any time
The patient previously received treatment with SL-401.
GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible
Patients randomized or previously randomized in any other Onyx-Sponsored Phase 3 trial.
Patients who have previously received treatment with LY2940680
Patients who have previously received radiation therapy to areas of the lung or mediastinum near target(s)
Subjects who have previously received hyperthermia in conjunction with either radiation therapy or chemotherapy are eligible.
Must have presumed resectable or partially resectable malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of surgery if not previously determined). Patients who have previously received AdV-tk + prodrug on this study may receive an additional AdV-tk + prodrug course at recurrence if eligibility criteria are still met.
Previously enrollment in this study
Patients with a feeding tube previously placed
Subject has previously been enrolled in this study and received at least 1 per protocol PLT transfusion
All subjects previously discontinued from an elotuzumab study for any reason
Survivors must not have previously received an SCP or are unwilling to receive one
No prior chemotherapy or radiation therapy for osteosarcoma; subjects who develop osteosarcoma as a second cancer are eligible if they have not previously received cisplatin, doxorubicin or other anthracyclines, or MTX
Previously on ADT
Patients who may have previously received SP-SAP on the study
Previously participated in any type of research study
Patients having previously undergone large surgical resections of the larynx or hypopharynx will be excluded
Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN003694-001)
No documentation of prior cytotoxic or other therapy for malignancy if such therapy was previously received; Note: This does not apply to patients with synchronous metastases at initial diagnosis
Previously randomized to this study.
Patients who have previously utilized art therapy at Maroone Cancer Center
Subjects who have previously completed primary treatment for a gynecologic malignancy
Phase I: Previously screened or not screened
Patient must not have previously had a breast MRI
If previously measured, known LVEF < 50%
CONTROL (HEALTHY) GROUP: If previously measured, known LVEF < 50%
Patients who have been previously vaccinated with vaccinia
Has previously participated in this study, has previously received bezlotoxumab, has received an experimental monoclonal antibody against C. difficile toxin B, or has received a vaccine directed against C. difficile or its toxins.
Patients who have previously received SCH727965
Has previously participated in a MK-8228 (letermovir) study
Any patient who previously underwent spinal surgery at these levels will be excluded to eliminate late postoperative changes
Have a previously diagnosed condition of dry mouth
Have a previously diagnosed condition of gum disease this included gingivitis, gingival bleeding and plaque
Patient has previously participated in this study.
Patient has previously received [18F]NaF in the last thirty days
Previously untreated sarcomas
Previously untreated subjects must have a lesion on an imaging study
Have not previously viewed the Pathways decision aid
Only subjects previously participating in two specific studies are eligible to enroll into this study. Enrollment is not open to subjects if not previously enrolled in studies B1871006 or B1871008.
All subjects are excluded unless previously participating in studies B1871006 or B1871008.
Subjects may have previously received pre-operative radiation therapy.
